We Claims:

The invention Claimed is:

1. A compound of formula I



Formula I

and pharmaceutically acceptable hydrates, solvates, enantiomers, and stereoisomers thereof;

wherein,

R1 independently represents Null,



,



,



,



,


,P

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,
OR



;

R_2 represents



, , ,



,



,



,



,



,



2. A compound of formula II



Formula II

and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;

wherein,

R1 represents Null,




,

,

,

OR

;

R_2 represents


,

,

,

,



,



,



,



,



,



,



or



;

RH independently represents


O
S
S
O
,

O
Cl
H
N
O
Cl
,

O
O
O
,

NH2
O
O
O
Br

O
S
S
OH
,

O
Cl
OH
H
N
Cl
,



or



.

3. A pharmaceutical composition comprising a compound of claim 1, and a pharmaceutically acceptable carrier.
4. The pharmaceutical composition of claim 18, wherein said pharmaceutical composition is formulated for oral administration, parenteral administration, ocular, topical administration, injection, subdermal, transdermal administration, oral solution, nasal spray, oral spray rectal administration, buccal administration or transmucosal administration.
5. The pharmaceutical composition of claim 19, are formulated for the treatment of glaucoma, presbyopia, IOP, cataract, dry eye and oGVHD.
6. A pharmaceutical composition comprising a compound of claim 2, and a pharmaceutically acceptable carrier.
7. The pharmaceutical composition of claim 21, wherein said pharmaceutical composition is formulated for oral administration, parenteral administration, ocular, topical administration, injection, subdermal, transdermal administration, oral solution, nasal spray, oral spray rectal administration, buccal administration or transmucosal administration.
8. The pharmaceutical composition of claim 22, are formulated for the treatment of glaucoma, presbyopia, IOP, cataract, dry eye and oGVHD.
9. A compound of the structure:


S
S
H
O
O

,


O
N+
O
S
S
O
O−

,

.